Theravance Biopharma Inc (TBPH) Given Average Rating of “Hold” by Brokerages

Shares of Theravance Biopharma Inc (NASDAQ:TBPH) have received a consensus rating of “Hold” from the nine brokerages that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $41.50.

A number of equities research analysts have issued reports on the company. Leerink Swann increased their price target on Theravance Biopharma from $45.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday. BidaskClub lowered Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 3rd. Robert W. Baird reaffirmed a “sell” rating and issued a $22.00 price target on shares of Theravance Biopharma in a research report on Wednesday, November 1st. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the company a “buy” rating in a research report on Wednesday, October 25th. Finally, ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Theravance Biopharma by 3.6% during the 2nd quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock worth $144,972,000 after acquiring an additional 126,393 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Theravance Biopharma by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock worth $127,379,000 after acquiring an additional 116,981 shares in the last quarter. State Street Corp raised its position in shares of Theravance Biopharma by 2.2% during the 2nd quarter. State Street Corp now owns 889,682 shares of the biopharmaceutical company’s stock worth $35,443,000 after acquiring an additional 19,428 shares in the last quarter. Northern Trust Corp raised its position in shares of Theravance Biopharma by 6.1% during the 2nd quarter. Northern Trust Corp now owns 530,049 shares of the biopharmaceutical company’s stock worth $21,117,000 after acquiring an additional 30,611 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Theravance Biopharma by 1.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 210,331 shares of the biopharmaceutical company’s stock worth $7,202,000 after acquiring an additional 2,624 shares in the last quarter. 86.04% of the stock is currently owned by institutional investors and hedge funds.

Shares of Theravance Biopharma (NASDAQ TBPH) opened at $27.35 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 7.53 and a quick ratio of 7.21. The stock has a market capitalization of $1,480.00, a PE ratio of -5.30 and a beta of 2.09. Theravance Biopharma has a 12-month low of $22.90 and a 12-month high of $43.44.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.05). Theravance Biopharma had a negative net margin of 1,604.87% and a negative return on equity of 99.43%. equities research analysts expect that Theravance Biopharma will post -4.84 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Theravance Biopharma Inc (TBPH) Given Average Rating of “Hold” by Brokerages” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://sportsperspectives.com/2018/02/09/theravance-biopharma-inc-tbph-given-average-rating-of-hold-by-brokerages.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply